To submit a manuscript please go to https://www.evise.com/profile/api/navigate/OGLA. This site is also available through http://www.ophthalmologyglaucoma.org/ or the American Academy of Ophthalmology at http://www.aao.org/.
Submissions are divided up into Article Types and Manuscript Categories. The main Article Types and their Manuscript Categories are listed below. Please select the appropriate Article Type to start the submission, then select the “Manuscript Category” when prompted in the online submission form. Please be aware that Ophthalmology Glaucoma will only infrequently consider basic science manuscripts, clinical trial baseline data and methods manuscripts, or clinical case reports.
Full Length Article
- Manuscripts – A “typical” submission; a manuscript that does not fall into any of the following categories:
- AAO Meeting Paper/AGS Meeting Paper – A manuscript based on material that has or will be presented at an American Academy of Ophthalmology Annual Meeting and/or American Glaucoma Society Annual Meeting. Ophthalmology has right of first refusal on these manuscripts.(See AAO/AGS Meeting Paper section below.)
Correspondence – Comments by readers about articles that have been published in Ophthalmology Glaucoma within 6 months of its online posting. Please see specific criteria for submission in the Correspondence section of this Guide.Editorial – Typically by invitation from the Editor-in-Chief. Please see specific criteria for submission in the Editorial section of this Guide.
- Systematic Review or Meta-analysis – Please see specific criteria for submission in the Systematic Review/ Meta-analysis in this Guide.
- Translational Science Reviews – Typically by invitation from the Editorial Board. Please see specific criteria for submission in the Translational Science Reviews section of this Guide.
- Manuscript to Report (Invited) – Typically by invitation from the Editorial Board. Please see specific criteria for submission in the Reports section of this Guide.
- Pictures & Perspectives – Photographs, photomicrographs, radiologic or other imaging studies, or procedural illustrations that depict novel features of clinically important entities. If accepted, the images will publish when space permits, and as a result it may take several months before they appear in print.
If you have questions about the submission process, please contact the Editorial Office by email at email@example.com or by phone at 415-447-0261. If you are having trouble logging in to Evise, please visit http://help.elsevier.com/app/answers/detail/a_id/204/p/7923/related/1 for more information or visit our Support Center.
User Name and Password
Evise is used for processing all submissions and relies on correct e-mail addresses for all authors and reviewers. Your user name and password are the same regardless of your role as author or reviewer.
IF YOU KNOW YOUR USER NAME AND PASSWORD:
- Log into the home page https://www.evise.com/profile/api/navigate/OGLA using your user name (primary email address) and password and hit enter or click “Login”
- Click on your name in blue text in top right corner of the screen and review your contact information. Only one email address can be listed. Please be sure you use an email that you frequently check and is the least likely to change should you relocate to a new institution. Here you can update all your current contact information and change your password. Please remember to click “Submit” to save changes before closing the window.
- Change data as needed – Be sure to click “Submit” on the bottom of the page. We greatly appreciate you taking the time to update your information.
- Go to Evise https://www.evise.com/profile/api/navigate/OGLA
- click on “Register Now” (next to the login) and fill in your first name, last name, e-mail address, and create a password. If you are already in the system, it will notify you. When you receive it, follow directions #2 and #3 above.
- If you have changed your email address relatively recently and Evise does not recognize you, we suggest you also try entering in your previous e-mail address so that you do not generate duplicate registrations within the system. If you have never registered as an author or reviewer:
- If you have never been in the system in any role (author or reviewer) go to the home page at https://www.evise.com/profile/api/navigate/OGLA click on “Register Now” and follow the steps provided on the website.
If you do not know your user name and password but believe you are in the system, please do the following:
If for any reason you cannot access your information or are not sure if you are in the system, please send an e-mail to firstname.lastname@example.org with your first name, last name, city and state or city and country as appropriate and your new e-mail address. The Editorial office can verify if you have an existing account.Author Checklist
Please ensure that the following items have been done prior to logging into Evise:
- ___ Designate one author as the corresponding author with contact details.
- ___ If the paper was previously rejected by another journal, please prepare and submit copies of the reviews and your responses to them in the Cover Letter.
- ___ Provide at least 2-6 Taxonomy topics on the submission form.
When uploading files, please make certain that:
- ___ Précis is 35 words or fewer and uploaded as the “Highlights” file.
- ___ Manuscript file contains a title page.
- ___ Manuscript file contains an abstract.
- ___ Manuscript file contains continuous line numbering.
- ___ Figures and tables are not embedded in the manuscript file; submit figures and tables as separate files.
- ___ Abstract conforms to the journal’s structured format.
- ___ Figures are in tiff format.
- ___ Tables include titles, brief description, and footnotes.
- ___ Online-only figures/tables are in PDF and properly labeled. Appropriate callouts are added to the manuscript file.
- ___ Acceptable File types are used (https://www.elsevier.com/__data/promis_misc/OPHTHA_Listofacceptablefiletypes.docx).
- ___ Use the active voice when writing the manuscript.
- ___ Spell out acronyms.
- ___ Spell-check and grammar-check your manuscript prior to submission.
- ___ Ensure that references are in the correct AMA style format.
- ___ Make certain that all references are cited in the text.
- ___ Obtain permission for use of copyrighted material from other sources.
Authors Contributorship Form
OtherConsort Agreement for a Randomized Controlled Trial Pictures & Perspectives Copyright
Submission declaration and verification
Submission of an article implies that the work described has not been published previously (except in the form of an abstract, a published lecture or academic thesis, see 'Multiple, redundant or concurrent publication' for more information), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in English or in any other language, including electronically without the written consent of the copyright-holder. To verify originality, your article may be checked by the originality detection service Crossref Similarity Check.
Find out how you can share your research published in Elsevier journals.
Green open access
Authors can share their research in a variety of different ways and Elsevier has a number of green open access options available. We recommend authors see our open access page for further information. Authors can also self-archive their manuscripts immediately and enable public access from their institution's repository after an embargo period. This is the version that has been accepted for publication and which typically includes author-incorporated changes suggested during submission, peer review and in editor-author communications. Embargo period: For subscription articles, an appropriate amount of time is needed for journals to deliver value to subscribing customers before an article becomes freely available to the public. This is the embargo period and it begins from the date the article is formally published online in its final and fully citable form. Find out more.
Once files are uploaded, please place them in the correct order for the submission PDF by clicking the “Order Files” button. The system will create a PDF of your uploaded files for your approval before completing the submission. If necessary, you may exit the system and return to approve the submission at your convenience. You will find it in your Author Tasks. Please review your submission and approve it, or, if necessary, make corrections and repeat the process until you are satisfied. Incorrect file formats or missing components will prevent the PDF of your submission from building. If any changes are required to the uploaded files, you will need to remove the original file and upload a new file with your corrections. Changes cannot be made to files once they have been uploaded into the system. At the last step, when you are ready to approve the submission and click “Complete Submission” you must also agree to the Ethics in Publishing statement. A link is provided to the statement and you agree to it by checking the box.
A Manuscript Number will be assigned during the submission process. Please use this number in all communications regarding your submission.Copyright
Upon acceptance of an article, authors will be asked to complete a 'Journal Publishing Agreement' (for more information on this and copyright, see https://www.elsevier.com/copyright). An e-mail will be sent to the corresponding author confirming receipt of the manuscript together with a 'Journal Publishing Agreement' form or a link to the online version of this agreement.
Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the Publisher is required for resale or distribution outside the institution and for all other derivative works, including compilations and translations (please consult https://www.elsevier.com/permissions). If excerpts from other copyrighted works are included, the author(s) must obtain written permission from the copyright owners and credit the source(s) in the article. Elsevier has preprinted forms for use by authors in these cases: please consult https://www.elsevier.com/permissions.Author rights
As an author you (or your employer or institution) have certain rights to reuse your work. For more information see https://www.elsevier.com/copyright.
Funding body agreements and policies
Elsevier has established a number of agreements with funding bodies which allow authors to comply with their funder's open access policies. Some authors may also be reimbursed for associated publication fees. To learn more about these agreements please visit https://www.elsevier.com/fundingbodies
• Articles are freely available to both subscribers and the wider public with permitted reuse
• An open access publication fee is payable by authors or on their behalf (e.g., by their research funder or institution)
• Articles are made available to subscribers as well as developing countries and patient groups through our universal access programs (https://www.elsevier.com/access).
Regardless of how you choose to publish your article, the journal will apply the same peer-review criteria and acceptance standards.For open access articles, permitted third party (re)use is defined by the following Creative Commons user licenses:
Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)This license allows others to distribute and copy the article for non-commercial purposes or include in a collective work (such as an anthology) as long as authors are properly credited and the article is not altered or modified.
The open access publication fee for this journal is USD 3300, excluding taxes. Learn more about Elsevier's pricing policy: https://www.elsevier.com/openaccesspricing.This journal has an embargo period of 12 months.
Use of inclusive language
Inclusive language acknowledges diversity, conveys respect to all people, is sensitive to differences, and promotes equal opportunities. Articles should make no assumptions about the beliefs or commitments of any reader, should contain nothing which might imply that one individual is superior to another on the grounds of race, sex, culture or any other characteristic, and should use inclusive language throughout. Authors should ensure that writing is free from bias, for instance by using 'he or she', 'his/her' instead of 'he' or 'his', and by making use of job titles that are free of stereotyping (e.g. 'chairperson' instead of 'chairman' and 'flight attendant' instead of 'stewardess').
Randomized controlled trials should be presented according to the CONSORT guidelines. At manuscript submission, authors must provide the CONSORT checklist accompanied by a flow diagram that illustrates the progress of patients through the trial, including recruitment, enrollment, randomization, withdrawal and completion, and a detailed description of the randomization procedure. The CONSORT checklist and template flow diagram are available online.
Registration of clinical trials
Registration in a public trials registry is a condition for publication of clinical trials in this journal in accordance with International Committee of Medical Journal Editors recommendations. Trials must register at or before the onset of patient enrolment. The clinical trial registration number should be included at the end of the abstract of the article. A clinical trial is defined as any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects of health outcomes. Health-related interventions include any intervention used to modify a biomedical or health-related outcome (for example drugs, surgical procedures, devices, behavioural treatments, dietary interventions, and process-of-care changes). Health outcomes include any biomedical or health-related measures obtained in patients or participants, including pharmacokinetic measures and adverse events. Purely observational studies (those in which the assignment of the medical intervention is not at the discretion of the investigator) will not require registration.
Please be sure all abbreviations/acronyms are spelled out at first use in the abstract and again at first use in the text. An abbreviation/acronym should appear first in parentheses immediately after the term or phrase to which it refers. Every abbreviation used in any table or figure should be defined in each corresponding legend.When writing the manuscript, use the active voice whenever possible.
A structured abstract is required for Manuscripts, AAO Meeting Papers, and Systematic Reviews or Meta-analyses. For Reports only: A 35-word unstructured abstract is required for editors'/reviewers' view only and will not publish with the report.
- Objective or Purpose: Concisely state the study goal.
- Design: Identify the study design using a phrase such as cross-sectional study, clinical trial, cohort study, etc. Study design types are summarized in the Study Design section of this guide. The CONSORT Worksheet is required for randomized controlled trials.
- Subjects, Participants, and/or Controls: Describe the persons or eyes studied and the controls if a separate control group is included.
- Methods, Intervention, or Testing: Describe the principal treatment(s), procedure(s), test(s), or observation(s) performed.
- Main Outcome Measures: Define the main parameter(s) being measured (e.g., intraocular pressure, visual acuity, degree of inflammation, etc.)
- Results: Summarize the principal measurements (data) obtained.
- Conclusions: State the conclusion(s) derived from the data analysis.
Abstracts for Systematic Reviews or Meta-Analyses should not exceed 350 words and must include 5 sections following the PRISMA guidelines (PRISMA Checklist: http://prisma-statement.org/documents/PRISMA%202009%20checklist.doc; and PRISMA flow diagram: http://prisma-statement.org/documents/PRISMA%202009%20flow%20diagram.doc):
- Topic: Provide an explicit statement of the specific clinical question being addressed with reference to a brief description of the participants, interventions (or exposures), comparators, and outcomes examined.
- Clinical relevance: Characterize the magnitude and importance of the condition; when relevant, define the current standard of care.
- Methods: Describe the key eligibility criteria for including studies in the systematic review, key databases searched and search dates, and methods of assessing the risk of bias in the individual included studies.
- Results: Summarize the number and type of included studies and participants, and relevant characteristics of studies; describe the results of main outcomes (benefits and harms), preferably indicating the number of studies and participants for each. If a meta-analysis was done, include summary measures and confidence intervals; report the direction of the effect or association (i.e., which group is favored) and size of the effect using language meaningful to clinicians and patients.
- Conclusion: Summarize the strengths and limitations of the evidence, your general interpretation of the results, and important implications.
AAO/AGS Meeting Papers and Posters
Ophthalmology has the right of first refusal on papers presented during the Academy's Annual Meetings, and Ophthalmology Glaucoma has right of second refusal for such papers on topics related to glaucoma. Presentations at the Academy's subspecialty day programs are exempt from this requirement (although submissions from such presentations are welcome). Authors seeking publication may submit their manuscript to the journal before, during, or after the Annual Meeting presentations. Please note on the cover page of the manuscript that it is derived from an Annual Meeting paper or poster. Please be sure to select “AAO Meeting Paper” or “AGS Meeting Paper” for the “Manuscript Category” please do not use “Manuscript” in these instances. A manuscript based on presentation at the AAO and/or AGS Annual Meeting can be submitted to other journals if Ophthalmology or Ophthalmology Glaucoma declines to accept it after review (as documented by a rejection letter from the journal office) or if a waiver is granted in writing by the Editor-in-Chief.
The journal requires acknowledgment of anyone who makes substantial contributions to a manuscript but does not qualify as an author. Please refer to the Authorship section of this guide, specifically regarding Ghost/Guest Authors. The journal does not allow ghost authors.
The journal does not print acknowledgments for those who participated in studies (e.g., patients), those who edited for grammar or formatting, or those who provided “helpful” or “moral” support or similar collegial aid to the authors. The journal does not publish acknowledgments of individuals whose service as employees contributed to a study, e.g., secretaries, clinic coordinators, technicians, ophthalmic photographers, or technologists.Astigmatism Reporting
For clarity and uniformity, manuscripts about astigmatism should adhere to terminology and graphical representations originally described by Alpins.1-3 An editorial by Reinstein et al outlines the argument for standardization.4
For details of the Alpins methodology and graphical reporting, please consult the following resources:
- Alpins N. Astigmatism analysis by the Alpins method. J Cataract Refract Surg. 2001;27:31-49.
- Alpins NA. Vector analysis of astigmatism changes by flattening, steepening, and torque. J Cataract Refract Surg. 1997;23:1503-1514.
- Alpins NA. A new method of analyzing vectors for changes in astigmatism. J Cataract Refract Surg. 1993;19:524-533.
- Reinstein DZ, Archer TJ, Randleman JB. JRS standard for reporting astigmatism outcomes of refractive surgery. J Refract Surg. 2014;30:654-659.
The journal adheres to the Uniform Requirements set by the International Committee of Medical Journal Editors (http://www.icmje.org/) for authorship. Each author must meet criteria for Authorship. The ICMJE recommends that authorship be based on the following 4 criteria:
- Substantial contributions to conception and design of the work; or the acquisition, analysis, or interpretation of data for the work; AND
- Drafting the work or revising it critically for important intellectual content; AND
- Final approval of the version to be published; AND
- Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
Please note that the journal does not allow ghost authorship, based on the definition of ghost authorship as the failure to designate an individual who has made a substantial contribution to the research or writing of a manuscript (JAMA. 2008;299(15):1800-1812). If it comes to light that a substantial contribution has not been disclosed, the journal shall advise the corresponding author and withdraw the submission.
The corresponding author is the person responsible for a submission and all communication with the journal regarding a submission. The corresponding author must notify the editors and editorial office, via the submission form, of the following:
- Acknowledgment of any guest author, defined as an individual who does not meet authorship criteria but has made a substantial contribution to the research or writing of a manuscript.
- Confirmation that there are no “ghost authors,” defined as an individual who has made a substantial contribution but does not qualify as an author and has not been disclosed to the editor.
- Submission of ICMJE conflict of interest and copyright forms from all authors; conflict of interest forms are required and requisite disclosures should be reported on the manuscript’s cover page.
- Submission of the Contributorship Form (see Downloadable Forms).
- Acknowledgment of funding by the US National Institutes of Health (NIH). Articles accepted for publication in Ophthalmology Glaucoma from authors who have indicated that the underlying research reported in their articles was supported by an NIH grant will be sent by Elsevier to PubMed Central for public access 12 months after publication. The version of the article provided by Elsevier is the final accepted version after peer-review but before copyediting.
- Confirmation that Institutional Review Board issues have been addressed in the Methods section of the main manuscript.
- Confirmation that the authors are aware the journal occasionally, only after acceptance of a submission and on a confidential basis and with no rights prior to embargo date, shares some information with the American Academy of Ophthalmology public relations staff and/or EyeNet staff.
If study group/writing committee authorship is used and the corresponding author is the study chair, please state this on the cover page. However, if he/she is not the study chair, please enclose with the submission a statement from the study chair that the group authorship as stated on the cover page and/or members of the responsible writing committee are both correct. The journal promotes transparency of authorship to editors, reviewers, and readers.
Members of the group can be listed in initial group papers in print and in subsequent papers, either by reference to an earlier manuscript, or at times for length and format reasons, in online supplemental material. Members are appropriately acknowledged by the byline “…for the XYZ Study Group” or “… on behalf of the XYZ Group.” If you believe group members are more appropriately acknowledged by including them as authors, each must meet authorship criteria and complete the required ICMJE authorship criteria, copyright assignment, and conflict of interest forms.With transparency and space limitations in mind, the following are the journal’s policies regarding study group/writing committee authorship:
- If an individual is authoring for a group (e.g., a Study Chair) it should be listed as
Henry A. Fiddle, MD for the Laser ROP Study Group
- Small study groups (≤ 10 members) can author as the group or they can list writing committee members names “and the XYZ Study Group” as long as all the members qualify as authors. Otherwise, only those who qualify should be listed and the remainder can be acknowledged.
Debra L Hanson, MS; Susan Y. Chu, PhD; Karen M. Farizo, MD; John W. Ward, MD; and the Adult and Adolescent Spectrum of HIV Disease Project Group
- Large study groups (>10 members) should not author a paper as an entity. In large groups it is not likely that every single member of the group or network contributed as required by the authorship criteria mentioned above. Large study groups should either list the writing committee members as authors and then “for the XYZ Study Group” or list “Writing committee for the XYZ Study Group*” as the author and the names of the writing committee members will be listed at the end of the article with the asterisk. Regardless, members of the writing committee must qualify as authors and complete the appropriate ICMJE authorship forms.
Debra L Hanson, MS; Susan Y. Chu, PhD; Karen M. Farizo, MD; John W. Ward, MD for the Adult and Adolescent Spectrum of HIV Disease Project Group OR The Writing Group for the DISC Collaborative Research Group* OR The DISC Collaborative Research Group Writing Committee*
Entering Authors into the Submission System
Enter the title, first and last name, email address, and country for all authors. The number of authors on the submission form must match the list on the title page. Be sure to indicate which author is the corresponding author by checking the appropriate box. All correspondence regarding a submission must come from and will be sent to the corresponding author only. Author order can be changed by changing number order next to the author's name, then clicking "Save" to update the order. Please do not have staff members list themselves as authors for the purpose of uploading files.
We encourage authors to use the American Joint Commission on Cancer TNM Classification scheme when describing patients with ophthalmic malignancies. AJCC Cancer Staging Manual. (7th ed. New York, NY: Springer; 2009). The classification scheme can also be found at https://cancerstaging.org/references-tools/Pages/What-is-Cancer-Staging.aspx.
A clinical trial is defined as any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes. With regards to the reporting of clinical trials, Ophthalmology's policies are similar to the policies of The New England Journal of Medicine (NEJM), and The Journal of the American Medical Association (JAMA) which can be viewed at http://jama.ama-assn.org/misc/authors.dtl.
Consistent with these policies, prospective clinical trial registration is required. Please state in the Methods section where the clinical trial registration information is publicly available. Satisfactory public databases include the NIH's http://www.clinicaltrials.gov and the site from the International Standard Randomized Controlled Trials at http://www.controlled-trials.com.For all manuscripts that report clinical trials, CONSORT guidelines must be followed, including submission of a CONSORT flow diagram and checklist.
Ophthalmology Glaucoma supports the National Institutes of Health Principles and Guidelines for Reporting Preclinical Research. Please refer to the following site for additional information: http://www.nih.gov/about/reporting-preclinical-research.htmConflict of Interest (financial disclosure)
Each co-author must complete an ICMJE Conflict of Interest Form and submit it to the corresponding author. Although the ICMJE form requires “potential” and “relevant” conflicts, to promote transparency we request authors to report all financial relationships. Mutual funds need not be listed. Such disclosure will not affect the review of the manuscript.
For further information, please refer to: Liesegang TJ, Schachat AP. Enhanced reporting of potential conflicts of interest: rationale and new form. Am J Ophthalmol. 2011:151:391-3.Liesegang TJ, Bartley GB. Toward transparency of financial disclosure. Ophthalmology. 2014;121:2077-9.
Liesegang TJ, Bartley GB. Footnotes, acknowledgments, and authorship: toward greater responsibility, accountability, and transparency. Ophthalmology. 2014;121:2297-8.All submissions must have the ICMJE Conflict of Interest Form completed and uploaded for each author preferably as part of the initial submission process, but no later than first revision. The form posted on the ICMJE website (http://www.icmje.org/coi_disclosure.pdf) and enclosed in our guide as a downloadable form includes instructions to help authors provide the correct information. For non-native English speakers, there is a glossary of terms that are used in the form.
Every published manuscript will have a blanket statement, inserted by the publisher; either "None of the authors has any conflicts of interest to disclose." OR "Authors with financial interests or relationships to disclose are listed after the references." Corresponding authors are asked to confirm or update conflict of interest statements as part of the final steps of manuscript acceptance with the journal office, prior to transmittal to the publisher.Copyright
Upon acceptance of an article, authors will be asked to complete a 'Journal Publishing Agreement' (for more information on this and copyright, see https://www.elsevier.com/copyright). An e-mail will be sent to the corresponding author confirming receipt of the manuscript together with a 'Journal Publishing Agreement' form or a link to the online version of this agreement.
Signed copyright forms state that the undersigned authors either own the copyright or have written permission to use all the material in their article. If authors are submitting any material to which they do not own copyright, they need to secure permission to use the copyrighted materials.NOTE: Once a manuscript has been accepted, the order of authorship (including adding or removing authors) cannot be changed without a written request to the editorial office from the corresponding author. This request must include a statement signed by all authors that they agree with the change along with a new copyright form, both signed by all authors. Specifically, if an author is removed, a letter from that author agreeing to his/her removal is required. The new copyright form must show the title and authors’ names in the order they should appear in print on the top of the form and include original signatures from each author; signature order does not matter. If the original authors are not able to agree among themselves on authorship changes, please withdraw the paper. Authorship changes cannot be submitted with proof changes. The publisher cannot approve such changes and it will delay publication of the manuscript.
Correspondence and Replies
Correspondence (previously Letters to the Editor) allows concise commentary about an article published in the journal within 6 months of its online posting. The text should raise a question for clarification, offer an alternative perspective, or explain a flaw in methodology or a perceived misinterpretation of data. The correspondence should address no more than three points. Correspondence should not be used as an avenue to introduce new material without subjecting it to typical peer review.
Submission: Signed ICMJE conflict of interest forms should be submitted along with your correspondence.Process: Correspondence is reviewed by the Editor-in-Chief, members of the Editorial Board, and, in rare instances, by outside reviewers. If the correspondence is accepted for publication, it is forwarded to the corresponding author of the original article for the opportunity to respond. If the invitation is accepted, both the correspondence and reply are edited and published together. If the invitation to reply is declined, the original correspondence may be processed and published by itself.
When the journal office accepts correspondence addressing an article, the corresponding author of the article being discussed will receive an email entitled “Invitation to reply to a letter to the editor regarding your recent Ophthalmology Glaucoma article” Authors of the original manuscript are given 10 days to submit a reply. All correspondence and replies are published online, although the material is listed in the print Table of Contents.When requested to revise a Correspondence, please submit a point-by-point file to demonstrate how the editor’s questions or recommendations were addressed. The point-by-point template can be accessed at: https://www.elsevier.com/__data/promis_misc/oph-template-form.docx.
Cover Letters are required for all new submissions. Please use the cover letter to note if your manuscript was previously submitted to this or any other journal (see “Rejection of Manuscripts” section of this guide), or to notify the editorial board or editorial office of any additional information.
Do not use drug trade names in titles. Please use the generic name in the abstract, as appropriate, but include the trade name once, in parentheses, after the first use of the generic name. Similarly, in the text, use the generic name, but include the trade name once, in parentheses, after the first use of the generic name.Device/Equipment Names
A device name is permitted in the title, abstract, and text. However, after the device has been identified at first use in the abstract and text, thereafter refer to it generically. In the case of equipment, include the manufacturer’s name, city, state, and/or country parenthetically at the first use in the text.Editorials
Editorials are usually solicited by the Editor-in-Chief, although unsolicited submissions will also be considered. Editorials may address clinical or non-clinical topics in summary form and generally do not exceed 1700 words, including references. Often editorials are linked with a particular manuscript awaiting publication; therefore, adherence to deadlines is critical. If a figure is desirable, please decrease the word count by approximately 200. The ICMJE conflict of interest form should be uploaded with initial submission and if accepted, copyright form will be collected during the production stage. Editorials, whether invited or unsolicited, undergo peer review.
English Editing Assistance
The journal office may return a submission and recommend professional editing prior to formal review. Authors who require editing to eliminate grammatical or spelling errors and to conform to correct scientific English may wish to use the English Language Editing service available from Elsevier’s WebShop http://webshop.elsevier.com/languageediting/ or visit the customer support site http://support.elsevier.com for more information. However, Ophthalmology Glaucoma neither endorses nor recommends any specific individual or service and professional editing does not ensure acceptance of a manuscript.
Figures (photographs, illustrations, or graphs) will be included in the final PDF but figure file names will not be visible to reviewers. Non-composite figures should be loaded to individual files and clearly identified. For all figures, the figure number must be entered in the file description field before uploading each figure. To upload figures, go to the “Upload Files” page of the submission form. Click “Upload Files” to browse your desktop for the files or drag and drop them into the window. Select “Figure” as the File Type. In the “Description” box enter the figure number for each figure file. Please do not upload legends here. Legends for print figures should be included at the end of the Manuscript file. Figures at revision should be uploaded as high resolution .tif or .eps files; one figure per file. Online-only supplemental figures must be PDF files with the legend included in the PDF; one figure per PDF file and uploaded as “e-Component” files.
Photographs (including those generated electronically from MRI, fluorescein angiography, perimetry, OCT, etc.) must be masked to prevent patient identification. Clinical photographs that permit identification of an individual (those exposing anything more than just the eyes) must be accompanied by a signed statement by the patient or guardian granting permission for publication of the images for educational purposes. All graphics, including composites (such as clinical photographs, fluorescein angiography, CT, MRI, OCT, photomicrographs, etc.) should be submitted at the actual size that they would be presented in the journal, i.e., 100% of their print dimensions to avoid scaling. The width should be no more than 7 inches.The publisher will not re-draw or rework photographs or other figures. Submit all figures in the order they appear in the legends. If there are 6 or more color pictures, a composite maybe preferred. However, only use composites that do not compromise figure integrity or quality. The completed composite must meet the guidelines for artwork submission. Composites must also be labeled using typed text in the corner of each image. Composites are encouraged for multi-panel figures (e.g., Fig 1A, 1B, 1C, 1D, 1E). Please see this chart for additional details: https://www.elsevier.com/__data/promis_misc/OPHTHAFigurechartupdated.pdf and Elsevier's Artwork and Media Instructions https://www.elsevier.com/authors/author-schemas/artwork-and-media-instructions.
- Physical dimensions of artwork must fit dimensions of the pages within the journal (i.e., width no more than 7 inches).
- Be consistent in font type and size used in the artwork (8-point Helvetica).
- Artwork must use recommended naming conventions. Some examples include fig1.tif (figure 1 in TIFF format). Ensure the file extension is present to allow format identification.
Please disclose all funding sources, public and private. On the title page please state “Financial Support: None” or provide the agency name and city, company name and city, fellowship name, and grant number. If there is financial support, please provide also one of the two following statements, “The sponsor or funding organization had no role in the design or conduct of this research.” OR “The sponsor or funding organization participated in (list those that are appropriate, e.g., the design of the study, conducting the study, data collection, data management, data analysis, interpretation of the data, preparation, review or approval) of the manuscript.”
Institutional Review Board
If the study involved human subjects, human-derived materials, or human medical records, please include one of the two following statements in the Methods section: “Institutional Review Board (IRB)/Ethics Committee approval was obtained” OR “IRB/Ethics Committee ruled that approval was not required for this study.” For Report submissions only: If institution's IRB does not require approval for case reports, provide an exemption letter or public URL that reiterates the policy that approval is not needed.
Legends for photographs, illustration, graphs, etc. should be written to be understandable on their own, without reference to the article’s text. Figures must be numbered consecutively as they appear in the text. Histological figures, stains, and magnifications should be noted in the legends. Any figure that has been published elsewhere should have an acknowledgment to the original source; a copy of the release to publish the figure, signed by the copyright holder, must also be submitted. Legends must identify all symbols, abbreviations, acronyms, or letters that appear on the prints. Table legends should be within the table. All abbreviations in each table must be defined even when repetitive to other tables.
Manuscript Text Format
Double-space the entire manuscript after the title page and add continuous line numbering to the manuscript file. The average published manuscript in Ophthalmology Glaucoma, including references, is 6 printed pages or less. This corresponds, depending on font size and printing, to 16-20 pages of double-spaced draft.
The title page should include the following information.
- a) Title: The title should be meaningful and brief (no longer than 135 characters); abbreviations should not be used. Please ensure the manuscript title on the cover page matches the title entered into the submission system.
- b) Authors: Provide first name, middle initial, last name, and no more than two advanced degrees. The journal does not print society affiliations. Indicate each author's affiliation during the course of the study in footnotes on the title page using superscript numbers, not symbols (e.g., John Smith1). Specifically identify the corresponding author. Please carefully review the Authorship section of this guide, which addresses authorship criteria, group/writing committee authorship, ghost authors, guest authors, corresponding authors, and related responsibilities. Verify numbers of authors when entering author names into the system.
- c) Meeting Presentation: If the material is under consideration for presentation or has been previously presented, supply the name, place, and date of the meeting. (e.g., the American Academy of Ophthalmology Annual Meeting, 20XX or the American Glaucoma Society Annual Meeting, 20XX). This is especially important for AAO Meeting papers as the journal has the right of first refusal for these manuscripts.
- d) Financial Support: Identify all sources, public, and private. On the title page please state “Financial Support: None” or provide the agency name and city, company name and city, fellowship name, and grant number. If there is financial support, please provide also one of the two following statements, “The sponsor or funding organization had no role in the design or conduct of this research.” OR “The sponsor or funding organization participated in (list those that are appropriate, e.g., the design of the study, conducting the study, data collection, data management, data analysis, interpretation of the data, preparation, review or approval of) the manuscript.”
- e) Conflict of Interest: A blanket statement that “no conflicting relationship exists for any author” is requested on the title page, if appropriate. Otherwise, the corresponding author should summarize the disclosures sent by each author and upload the ICMJE COI form of each author.
- f) Running head: The running head, also known as the short title, which appears on the top of each right hand published page of the manuscript, should be a maximum of 60 characters.
- g) Address for reprints
- a. Introduction: Without a heading, the two- to three-paragraph introduction should explain why the study was done and in particular what hypothesis is being tested. The introduction should refer only to the most pertinent past publications and should not be an extensive review of the literature.
- b. Methods, Intervention, or Testing: This section should be written with sufficient detail to permit others to duplicate the work. Also required are the following, as appropriate within the methods section:
FOR HUMAN SUBJECTS:
- Informed Consent - Manuscripts reporting the results of experimental investigation on human subjects must include a statement that informed consent was obtained (see Ophthalmology 2003;110:1074-5).
- IRB/Ethics Committee - Human subjects/materials/medical records - If the study involved human subjects, human-derived materials or human medical records, please include one of the following statements in the Methods section: "Institutional Review Board (IRB)/Ethics Committee approval was obtained" OR "IRB/Ethics Committee ruled that approval was not required for this study."
- Declaration of Helsinki - A statement is required that the described research adhered to the tenets of the Declaration of Helsinki.
- Clinical Trial Registration - A statement in the Methods confirming where the clinical trial is registered and publicly available. (See Clinical Trial Registration for more detailed information.)
- Authors are encouraged to use the American Joint Commission on Cancer TNM Classification scheme when describing patients with ophthalmic malignancies (AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer; 2009). The classification scheme can also be found at https://www.cancerstaging.org/references-tools/Pages/What-is-Cancer-Staging.aspx
- If animals were used in a study, the notice of approval by the appropriate Institutional Animal Care and Use Committee should be included in the Methods section of the manuscript.
- c. Results: Results should be concise. Information presented in tables should not be repeated in the text.
- d. Discussion: The discussion should be restricted to interpretation and application of the study’s notable findings. Discussion is the final section of a manuscript. Please do not insert a conclusion section; only the abstract has a conclusion section.
Online Supplemental Materials
Because space in Ophthalmology Glaucoma is highly competitive, some supplemental materials are published online only. Such supplements generally include tables, charts, figures, etc. that would further enhance a published article but for which there is insufficient room in the print edition.
When opting for an online supplement, add a reference to it in parentheses after the mention of the information to appear online: For example, “…as shown in Table N (available at at http://www.ophthalmologyglaucoma.org).” Online tables or figures should be numbered consecutively as they appear in the text, in the same sequence as printed figures or tables. Also, add a statement to the title page that should read similar to “This article contains additional online-only material. The following should appear online-only: Figures X, Y, Z and Table N.” All online-only supplemental files must be submitted as PDF files. One table, figure, or appendix per PDF file. Please note that these files will not be copyedited or composed and will be posted online as they appear submitted.All supplemental materials must follow the same criteria as if they were to appear in print. For example, tables must be able to stand alone with all abbreviations, references, etc. identified. Table legends would include definitions for the abbreviations, if any. Supplemental Figures must include the legend with the image in the PDF file.
Permission to Use Copyrighted Materials
Permission requests should be submitted to: Elsevier Health Sciences Rights Department, Global Rights Department, Oxford, United Kingdom; phone: 44-(0)1865-843830; fax: 44-(0)1865-853333. Requests may also be completed online; Email: email@example.com. However, it is preferable to submit any requests via the online form at https://www.elsevier.com/authors/obtain-permission as it ensures that Global Permissions receives the most complete information regarding your request.
Permission to use materials to which others hold copyright in a submission to Ophthalmology Glaucoma.The copyright form states that the author either owns the copyright or has written permission to use all the material in a submission. Examples include a clinical image/chart that was published in another journal or book, or a photograph of an ophthalmic device obtained from a pharmaceutical company. In most cases, permission can be obtained by e-mailing the publisher or company and explaining specifically what the author wishes to use, where (print and online versions of Ophthalmology Glaucoma), and why (in an article entitled XXXXX). Most copyright holders will reply with a “permission granted” letter which should be uploaded with the submission. Please allow ample time (typically 3-6 weeks) to receive permissions.
Pictures & Perspectives
The journal welcomes submission of high-quality photographs, photomicrographs, radiologic or other imaging studies, or procedural illustrations that depict novel features of clinically important entities. Single images or a related pair of images may be submitted and the accompanying legend should be 100 words or fewer. There is a limit of three authors. If accepted, the submission will be published when space permits.
All full-length manuscripts must include a précis of 35 words or fewer summarizing the main finding/outcome of the study. The précis should not duplicate the abstract conclusion. If the paper is published, the précis will appear under the title in the Table of Contents. The précis is submitted as a separate file and should not be included in the manuscript file. Please refrain from using abbreviations/acronyms in the précis. The précis should be uploaded as the “Highlights” file type.
The journal will not consider manuscripts that have appeared in other journals, in part or in total, except in special circumstances approved by the Editor-in-Chief. Likewise, updates of previously published studies that add minimal new information to an existing publication will not be considered. Overlap between patient groups described in serial manuscripts must be acknowledged, and references to previous publications that include the same patients must be provided. Authors uncertain as to whether specific data might be considered prior or repetitive publication should alert the Editor-in-Chief on their cover letter and provide copies of the publications in question.
To decrease the risk of unintentional plagiarism, and potential copyright violations, please consider analyzing your manuscript with plagiarism detection software prior to submission. Several programs are commercially available. The publisher uses iThenticate to verify the originality of written work when a manuscript is received. If duplicative text from published sources, whether from the author(s) previous work or not, is identified without proper citation, the manuscript cannot be considered for peer review and will be returned to the authors. For additional information, please consult: Bartley GB, Albert DM, Liesegang TJ. Choosing Our Words Carefully: Plagiarism in the Internet Age. Ophthalmology. 2014;121:807-808. Available at http://www.aaojournal.org/article/S0161-6420%2813%2901249-9/fulltext.Precedence
Authors who claim precedence for an idea, observation, or therapy should describe the literature search methodology used to support their assertion.
Indicate references by (consecutive) superscript Arabic numerals in the order in which they appear in the text. The numerals are to be used outside periods and commas, inside colons and semicolons. For further detail and examples, please refer to the AMA Manual of Style, A Guide for Authors and Editors, Tenth Edition, ISBN 0-978-0-19-517633-9.
Most manuscripts in Ophthalmology Glaucoma are neither intended to be review articles nor require encyclopedic referencing. Twenty or 30 references suffice for the majority of manuscripts and nearly all can be presented with less than 40. This limitation does not apply to Systematic Reviews or Meta-analyses.
Reference to a journal publication:1. Van der Geer J, Hanraads JAJ, Lupton RA. The art of writing a scientific article. J Sci Commun. 2010;163:51-59.
Reference to a book:2. Strunk W Jr, White EB. The Elements of Style. 4th ed. New York, NY: Longman; 2000.
Reference to a chapter in an edited book:3. Mettam GR, Adams LB. How to prepare an electronic version of your article. In: Jones BS, Smith RZ, eds. Introduction to the Electronic Age. New York, NY: E-Publishing Inc; 2009:281-304.
Reference to a website:4. Cancer Research UK. Cancer statistics reports for the UK. http://www.cancerresearchuk.org/aboutcancer/statistics/cancerstatsreport/; 2003 Accessed 13.03.03.
Dataset:5. Oguro M, Imahiro S, Saito S, Nakashizuka T. Mortality data for Japanese oak wilt disease and surrounding forest compositions, Mendeley Data, v1; 2015. http://dx.doi.org/10.17632/xwj98nb39r.1.
Reporting Refractive Surgery Outcomes and Astigmatism
Astigmatism_Reporting_links_to_Reporting_Refractive_Surgery_Outcomes_and_AstigmatismWhen reporting refractive surgery outcomes, please include 6 graphs to illustrate the following (references 1-3):
- Uncorrected distance visual acuity
- Change in corrected distance visual acuity
- Spherical equivalent (attempted versus achieved)
- Spherical equivalent refractive accuracy
- Spherical equivalent refraction stability
- Refractive astigmatism
- Waring GO III, Reinstein DZ, Dupps WJ, Kohnen T, Mamalis N, Rosen ES, Koch DD, Obstbaum SA, Stulting RD. Standardized graphs and terms for refractive surgery results. J Refract Surg 2011;27:7-Erratum in J Refract Surg 2011;27:88.
- Reinstein DZ, Waring GO III. Graphic reporting of outcomes of refractive surgery. J Refract Surg 2009;5:975-8.
- Waring GO III. Standard graphs for reporting refractive surgery. J Refract Surg 2000;16:459-66. Erratum in J Refract Surg 2001;17:following table of contents.
- Alpins N. Astigmatism analysis by the Alpins method. J Cataract Refract Surg 2001;27:31-49.
- Alpins NA. Vector analysis of astigmatism changes by flattening, steepening, and torque. J Cataract Refract Surg 1997;23:1503-14.
- Alpins NA. A new method of analyzing vectors for changes in astigmatism. J Cataract Refract Surg 1993;19:524-33.
- Reinstein DZ, Archer TJ, Randleman JB. JRS standard for reporting astigmatism outcomes of refractive surgery. J Refract Surg 2014;30:654-9. Erratum in: J Refract Surg 2015;3:129.
Reports are typically submitted after invitation from the Editorial Board. Specifically, some full-length manuscripts contain noteworthy information that can be presented in a more concise communique. The Editorial Board may invite the authors to abridge their work, taking into consideration suggestions for revision in the initial reviews, and resubmit the paper as a Report. The submission should be double-spaced and include a title of not more than 80 characters (spaces included). Reports do not exceed 1000 words or include more than 5 references, and may feature one figure, graph, chart, or concise table on the print version. Two additional items can be included as online supplemental material. Please insert “(available at available at
Systematic reviews seek to collect and critically assess all evidence that fits pre-specified criteria to answer a clinical question pertaining to the cause, diagnosis, prognosis, prevention, or therapy for a condition. A systematic review may contain a meta-analysis, which uses statistical methods to combine results from similar but independent studies.
Features of a systematic review include a clearly stated set of objectives with pre-defined eligibility criteria for studies; an explicit, reproducible methodology; a systematic search that attempts to identify all studies that would meet the eligibility criteria; an assessment of the validity of the findings of the included studies, for example through the assessment of risk of bias; and a systematic presentation, and synthesis of the characteristics and findings of the included studies (Higgins JPT, Green S (editors). Chapter 1. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011).It is possible to conduct a systematic review and meta-analysis of the evidence supporting any type of research question, whether the question is about intervention effectiveness or harm, etiology, prognosis, diagnostic accuracy, toxicity, incidence, or prevalence. Where intervention effectiveness questions are typically addressed by randomized controlled trials, most other questions are addressed using observational studies. Systematic reviews may be conducted for human or animal studies, in vivo or in vitro.
For standards and classic references in conducting systematic reviews and meta-analyses, please refer to:
- Institute of Medicine.Finding what works in health care: standards for systematic reviews. 2011.
- Chandler J, Churchill R, Higgins J, Tovey D. Methodological standards for the conduct of new Cochrane Intervention Reviews. Version 2.2. 17 December 2012.
- Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011.
- Handbook for Diagnostic Accuracy Reviews [Draft]
- Little J, Higgins JPT (editors). The HuGENE™ HuGE Review Handbook, version 1.0. Guidelines for systematic review and meta-analysis of gene disease association studies (see also Systematic Reviews of Genetic Association Studies, PLoS Medicine 2009;6(3):e1000028)
- Systematic Reviews. CRD's guidance for undertaking reviews in health care. Centre for Reviews and Dissemination, University of York, 2009
- A systematic review and/or meta-analysis of randomized controlled trials, please follow the PRISMA guidelines for reporting;
- A systematic review and/or meta-analysis of observational studies, please follow the MOOSE guidelines for reporting.
The title should clearly describe the research question and identify the report as a systematic review, meta-analysis, or both in the subtitle. (Example: Anti-vascular endothelial growth factor for neovascular age-related macular degeneration – A systematic review and meta-analysis.)Précis:
The précis should indicate a new insight the article offers or a principal controversy that is addressed.Structured Abstracts:
Abstracts for systematic reviews and meta-analysis must be limited to 350 words and include five sections following the PRISMA guidelines:
- Topic: provide an explicit statement of the specific clinical question being addressed with reference to a brief description of the participants, interventions (or exposures), comparators, and outcomes examined.
- Clinical relevance: characterize the magnitude and importance of the condition; when relevant, define the current standard of care.
- Methods: describe the key eligibility criteria for including studies in the systematic review, key databases searched and search dates, methods of assessing the risk of bias in the individual studies.
- Results: summarize the number and type of included studies and participants, and relevant characteristics of studies; describe the results of main outcomes (benefits and harms), preferably indicating the number of studies and participants for each. If a meta-analysis was done, include summary measures and confidence intervals; report the direction of the effect or association (i.e., which group is favored) and size of the effect using language meaningful to clinicians and patients.
- Conclusion: summarize the strengths and limitations of the evidence, your general interpretation of the results, and important implications.
The text should use standard journal formatting and be divided into four distinct sections. The brief descriptions below are gathered from the PRISMA Checklist: http://prisma-statement.org/documents/PRISMA%202009%20checklist.doc and PRISMA flow diagram: http://prisma-statement.org/documents/PRISMA%202009%20flow%20diagram.doc, the MOOSE guidelines, and the Standards for the Reporting of Cochrane Intervention Reviews. The text should report institutional review board approval or exemption, financial disclosures and potential conflicts of interest of the authors, and funding sources of the review.
2. Methods: The methods section should include the following subheadings:
- Eligibility criteria for considering studies for this review: state eligibility criteria for participants, interventions (or exposures) and comparators, and eligible study design(s) if applicable. Define primary and secondary outcomes of the review and state whether an article had to report measurement of at least one of the outcomes to be eligible. If so, provide rationale.
- Search methods for identifying studies: list all information sources searched, including databases, trial registries, websites, difficult-to-access literature (e.g., grey literature, conference proceedings), reference lists of included studies, and whether individuals or organizations were contacted. For all searches, provide the date of the last search and whether there was any time period or language restriction. Present the exact full search strategy (or strategies) used for at least one database in an Appendix with sufficient detail to permit replication. Report which software was used to manage the records identified and eligibility status.
- Study selection: describe the process for selecting studies, how many people were involved at each step of the review, whether any steps were done by more than one person, and if so whether they worked independently and how different opinions were resolved.
- Data collection and risk of bias assessment: List and define data items extracted from the reports of included studies. Describe methods used for assessing risk of bias of included studies (risk of bias is a formal assessment of what is often considered study “quality”), and how this information was used in any data synthesis. Describe the process for data extraction and risk of bias assessment, how many people were involved at each step, whether any steps were done by more than one person, and if so whether they worked independently and how different opinions were resolved. Report the software used for data collection and management.
- Data synthesis and analysis: state the methods for combining results across studies, which include qualitative synthesis (see Chapter 4, section on “Qualitative Synthesis of the Body of Evidence; Finding what works in health care: standards for systematic reviews) and quantitative synthesis (i.e., meta-analysis). State the summary measures used to quantify the treatment effect or association such as risk ratio, odds ratio, and difference in means. Describe methods for assessing clinical, methodological, and statistical heterogeneity (e.g., I2 statistic, tau-squared, statistical test). Describe methods for additional analyses such as meta-regression, subgroup analysis, and sensitivity analysis, if done, indicate which were pre-specified. State the statistical software used for analysis. Indicate whether a systematic review protocol exists, if so, where and how it can be accessed; and if available, provide systematic review registration information including registration number.
3. Results: Provide numbers of studies retrieved, screened, assessed in full for eligibility, included in the review, and included in the meta-analysis, with reasons for exclusion at each stage, ideally with a flow diagram. Present characteristics of included studies including information on the study design, participants, interventions (or exposures) and comparators, outcomes, and source of funding, ideally in a table. Present domain-based risk of bias assessment of each study, ideally in a table or a figure. Composite quality scores and scales are discouraged. For all outcomes considered, irrespective of the direction or strength of the results, present, (1) simple summary data for each group, and (2) estimates of treatment effect (or association) between groups with a measure of statistical uncertainty (e.g., confidence intervals). If meta-analysis was done, report meta-analytical results ideally with a forest plot, number of studies and participants for each meta-analysis, as well as measures of statistical heterogeneity. Present results of any additional analyses (such as meta-regression, subgroup analysis, and sensitivity analysis) if done. Provide a thoughtful qualitative synthesis by analyzing the nature, strengths, and weaknesses of the evidence, and developing a deeper understanding of how an intervention might work (or not), or whether a true association exists, for whom and under what circumstances.
4.Discussion: Summarizes the main findings including the strength of evidence for each main outcome. Provide a general interpretation of the evidence considering their relevance to key stakeholders, including patients, healthcare providers, researchers, payers, and policy makers. A Summary of Findings or GRADE table is optional. Discuss limitations at study and outcome level (such as risk of bias), and at review level (such as incomplete retrieval of identified studies, reporting biases). Provide a general interpretation of the results in the context of other evidence, and implications for practice and future research.In the cover letter to the Editor, please state explicitly (1) whether reporting guidelines have been followed, if so, which reporting guidelines; (2) whether the exact full search strategy (or strategies) used for at least one database was presented in an Appendix with sufficient detail to permit replication. Failure to follow the reporting guidelines or upload the search strategy may result in delay in review or rejection of the manuscript. Please submit a PRISMA worksheet and diagram as separate files.http://prisma-statement.org/documents/PRISMA%202009%20flow%20diagram.doc
Translational Science Reviews
Translational Science Reviews aim to provide authoritative summaries of state-of-the-art research that bridges the gap between basic and clinical science and which may have broad clinical impact within a few years. For example, in the years prior to the FDA approval of anti-VEGF drugs to treat neovascular age-related macular degeneration, an article in this section might have summarized the relevant basic research that supported Phase 1 human studies for anti-VEGF drugs that are now widely used. Manuscripts should be broadly accessible as the intended audience includes ophthalmologists whose primary focus is usually clinical practice. Please avoid jargon and do not assume that laboratory techniques will be understood by all readers. Translational Science Reviews are usually solicited by the editor for this section, Marco Zarbin, MD, PhD. Suggestions for topics are welcome, however, and can be directed to Dr. Zarbin (send suggestions to (firstname.lastname@example.org) and add “TSR” in the subject line).
Statistical methods must be identified in table footnotes, illustration legends, or text explanations. Software programs used for complex statistical analyses must be identified to enable reviewers to verify calculations. For manuscripts in which the study conclusions infer equivalency in treatment effect, a sample size calculation and power analysis should be included. Levels for alpha and beta errors should be clearly stated in the Methods section of the Abstract and text. Authors should state the clinically significant difference that was used to determine the power calculation. The journal strongly advises statistical consultation about data collection and analysis.
We follow The New England Journal Medicine’s guidelines for reporting P values: Except when one-sided tests are required by study design, such as in non-inferiority trials, all reported P values should be two-sided (except when one-sided tests are required by study design). In general, P values larger than 0.01 should be reported to 2 decimal places, those between 0.01 and 0.001 to 3 decimal places; P values smaller than 0.001 should be reported as P < 0.001. Notable exceptions to this policy include P values arising in the application of stopping rules to the analysis of clinical trials and genetic-screening studies. For tables comparing treatment or exposure groups in a randomized trial (usually the first table in the trial report), significant differences between or among groups should be indicated by * for P < 0.05, ** for P < 0.01, and *** for P < 0.001 with an explanation in the footnote if required. The body of the table should not include a column of P values.Study Design
Authors are asked to describe the design of their study as part of the structured abstract. Doing so serves several purposes. It encourages authors to give careful thought to what they have actually done, it provides a useful shortcut for editors and reviewers to categorize the submission, and it gives the reader a useful descriptor of the type of study that was performed.
The CONSORT Worksheet http://www.consort-statement.org/Media/Default/Downloads/CONSORT%202010%20Checklist.doc for randomized controlled trials has been required since 1996 and is available online. The following chart (https://www.elsevier.com/__data/promis_misc/OPHTHA_STUDY_DESIGN.docx) provides basic information regarding study designs.Tables
Tables require substantial space; please give careful consideration to the number of tables submitted and design tables to fit on one formatted page. The information should not be extensively iterated in the text. Place the information in the text or in a table but not both.
Each table must be titled and numbered consecutively as mentioned in the text. Each column must have a heading. Terminology used within tables should be able to stand independently, without the requirement of explanation from the text. Use abbreviations and acronyms only if imperative for reasonable table formatting. All abbreviations and acronyms must be explained in the table legend. References for tables should be included in the main reference list. If unpublished data or abstract need to be referenced in a table, please place it as a footnote.Tables for print publication must be uploaded as individual Word documents, one table per file. If a table is longer than one page in Microsoft Word, it may be too large to print and would work better as an online-only Supplemental Table. Online-only Supplemental Tables must be uploaded as PDF files, one table per PDF file. Supplemental Tables must be uploaded as “e-Component” file types to your submission.
If submitting video as an online supplement, add a reference to it in parentheses at an appropriate place within the text of the manuscript. Also, add a statement to the title page that should read similar to “This article contains a video as additional online-only material. The following should appear online-only: Clip 1, Clip 2 and Clip 3.” The materials will be archived with the online version on the publisher’s website http://www.aaojournal.org/ and accessible through Medline and other online databases.
- Maximum: 8 minutes total. We recommend several smaller clips that do not exceed 8 minutes.
- Size: recommended size 10-50 MB, and the maximum size is 100 MB.
- File extension types: .MPG (MPEG-1 or 2), .AVI, .MOV
- Upload a still image of each video clip.
- Audio commentary to describe the video is highly recommended. Please do not use background music.
- Within the submission, there must be a brief legend describing contents of the video and indicates the viewing order.
- Video files should be loaded with the submission into the electronic submission system. File names should correspond to video legends.
- On the title page include “This manuscript contains [insert number of video clips].
- Upload with submission using the “multimedia” file type.
Review and Publication Process
It is the corresponding author’s responsibility to check periodically the status of his/her manuscript. An email with a decision will be sent with instructions to the corresponding author to go to the online submission site if a revision is warranted.
If invited to revise a manuscript, the corresponding author will receive an email that contains the revise decision as well as the reviewers’ and/or editors’ comments. Log on as an author to https://www.evise.com/profile/api/navigate/OGLA with your user name and password. The manuscript will be in the author menu under “My submissions that need revision”
Instructions are provided on how to upload revised files and replace old ones in the “Upload Files” section. The following File Types are required to submit a revised article:
- Manuscript File (the clean revised version)
- Revised Manuscript File with Track Changes
- Highlights (Précis)
- Author Agreement (Contributorship Form)
- Conflict of Interest (ICMJE form, one per author)
- Cover Letter
- Response to Reviewers (Point-by-Point response)
- Point-by-point response: Please include a point-by-point response to each of the comments from the reviewer(s), editor(s), and/or editorial office. One technique that has proved useful both for authors and the Editorial Office is to create a 3-columned table, in a Word file, to summarize your revisions. (See templatehttps://www.elsevier.com/__data/promis_misc/oph-template-form.docx and samplehttps://www.elsevier.com/__data/promis_misc/oph-sample-form.docx.) In the first column, list the reviewer's suggestion, question, or comment. In the second column, outline your response. If you disagree with the reviewer, please explain your reasoning. In the third column, specify where in the manuscript you have made any changes. Adding line numbers to the manuscript file and referring to specific line numbers will be useful in determining which parts of the manuscript changed. Please ensure that revisions in the text are also changed in any relevant tables or figures.
- References: At first revision, please review the reference format style guide and ensure that references are in the correct format.
- To expedite processing of a revised manuscript, please provide a photocopy of the title page (including journal name, volume number, year, page numbers) of any work cited that was published prior to 1970 in the United States. This information can be submitted as “related file.”
- Figures: Please note any changes to figures in the point-by-point response.
- If applicable, the revision decision letter will provide instructions on how to prepare figures to meet specific artwork guidelines for the publisher. If you cannot meet these guidelines, contact the editorial office before submitting your revisions.
- Please insert into the text at first mention of the supplemental figures “(available at www.aaojournal.org)” as well as specify on the cover page which figures are to be online-only supplemental materials.
- Authors: Please ensure the manuscript title on the cover page matches the title entered into the submission system. Any changes to authors require written explanation, as detailed above under “Authorship.”
- File submission: Please upload two versions of your revised manuscript -- one showing “track changes” and one that is “clean.” Do not submit more than one version of any other file type unless specifically requested by the editorial office. Each file, revised or not, should be the current version of the submission. If not done with the initial submission, ICMJE conflict of interest forms from all authors and the Contributorship Form must be included at revision.
By Other Journals
Rejection by another journal does not compromise consideration by Ophthalmology Glaucoma. Authors are required to inform the Editor-in-Chief of rejection by another journal on the cover letter and include copies of the previous review commentary and the authors’ responses. Please use the point-by-point response template: https://www.elsevier.com/__data/promis_misc/oph-template-form.docxAppeals Regarding Manuscripts Rejected by Ophthalmology Glaucoma
Ophthalmology Glaucoma is able to accept a relatively small percentage of submissions received. Therefore, many good manuscripts have to be declined, oftentimes despite favorable peer reviews. If your paper is rejected but the reviews are accurate, please do not appeal the decision and request additional reviews. Doing so distracts the journal's editors/reviewers from evaluating submissions and editorial staff from processing other manuscripts and is unfair to the authors of those papers. If, however, the reviewer or editor assessments are reconsidered, the Editor-in-Chief will entertain an appeal and reopen the manuscript's file.
Occasionally, a manuscript is rejected but the Editorial Board offers the option to resubmit a revised, abridged version as a Report. Please see the Report section for details.Peer review
This journal operates a single blind review process. All contributions will be initially assessed by the editor for suitability for the journal. Papers deemed suitable are then typically sent to a minimum of two independent expert reviewers to assess the scientific quality of the paper. The Editor is responsible for the final decision regarding acceptance or rejection of articles. The Editor's decision is final. More information on types of peer review. Material and methods
Provide sufficient details to allow the work to be reproduced by an independent researcher. Methods that are already published should be summarized, and indicated by a reference. If quoting directly from a previously published method, use quotation marks and also cite the source. Any modifications to existing methods should also be described. Discussion
This should explore the significance of the results of the work, not repeat them. A combined Results and Discussion section is often appropriate. Avoid extensive citations and discussion of published literature.
If there is more than one appendix, they should be identified as A, B, etc. Formulae and equations in appendices should be given separate numbering: Eq. (A.1), Eq. (A.2), etc.; in a subsequent appendix, Eq. (B.1) and so on. Similarly for tables and figures: Table A.1; Fig. A.1, etc.
Although a graphical abstract is optional, its use is encouraged as it draws more attention to the online article. The graphical abstract should summarize the contents of the article in a concise, pictorial form designed to capture the attention of a wide readership. Graphical abstracts should be submitted as a separate file in the online submission system. Image size: Please provide an image with a minimum of 531 × 1328 pixels (h × w) or proportionally more. The image should be readable at a size of 5 × 13 cm using a regular screen resolution of 96 dpi. Preferred file types: TIFF, EPS, PDF or MS Office files. You can view Example Graphical Abstracts on our information site.
Authors can make use of Elsevier's Illustration Services to ensure the best presentation of their images and in accordance with all technical requirements.
Highlights are a short collection of bullet points that convey the core findings of the article. Highlights are optional and should be submitted in a separate editable file in the online submission system. Please use 'Highlights' in the file name and include 3 to 5 bullet points (maximum 85 characters, including spaces, per bullet point). You can view example Highlights on our information site.
Define abbreviations that are not standard in this field in a footnote to be placed on the first page of the article. Such abbreviations that are unavoidable in the abstract must be defined at their first mention there, as well as in the footnote. Ensure consistency of abbreviations throughout the article.
Collate acknowledgements in a separate section at the end of the article before the references and do not, therefore, include them on the title page, as a footnote to the title or otherwise. List here those individuals who provided help during the research (e.g., providing language help, writing assistance or proof reading the article, etc.).
List funding sources in this standard way to facilitate compliance to funder's requirements:
Funding: This work was supported by the National Institutes of Health [grant numbers xxxx, yyyy]; the Bill & Melinda Gates Foundation, Seattle, WA [grant number zzzz]; and the United States Institutes of Peace [grant number aaaa].It is not necessary to include detailed descriptions on the program or type of grants and awards. When funding is from a block grant or other resources available to a university, college, or other research institution, submit the name of the institute or organization that provided the funding.
If no funding has been provided for the research, please include the following sentence:This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Math formulae
Please submit math equations as editable text and not as images. Present simple formulae in line with normal text where possible and use the solidus (/) instead of a horizontal line for small fractional terms, e.g., X/Y. In principle, variables are to be presented in italics. Powers of e are often more conveniently denoted by exp. Number consecutively any equations that have to be displayed separately from the text (if referred to explicitly in the text).
Footnotes should be used sparingly. Number them consecutively throughout the article. Many word processors can build footnotes into the text, and this feature may be used. Otherwise, please indicate the position of footnotes in the text and list the footnotes themselves separately at the end of the article. Do not include footnotes in the Reference list.
Whilst it is accepted that authors sometimes need to manipulate images for clarity, manipulation for purposes of deception or fraud will be seen as scientific ethical abuse and will be dealt with accordingly. For graphical images, this journal is applying the following policy: no specific feature within an image may be enhanced, obscured, moved, removed, or introduced. Adjustments of brightness, contrast, or color balance are acceptable if and as long as they do not obscure or eliminate any information present in the original. Nonlinear adjustments (e.g. changes to gamma settings) must be disclosed in the figure legend.
• Make sure you use uniform lettering and sizing of your original artwork.
• Embed the used fonts if the application provides that option.
• Aim to use the following fonts in your illustrations: Arial, Courier, Times New Roman, Symbol, or use fonts that look similar.
• Number the illustrations according to their sequence in the text.
• Use a logical naming convention for your artwork files.
• Provide captions to illustrations separately.
• Size the illustrations close to the desired dimensions of the published version.
• Submit each illustration as a separate file.
A detailed guide on electronic artwork is available.
You are urged to visit this site; some excerpts from the detailed information are given here.
If your electronic artwork is created in a Microsoft Office application (Word, PowerPoint, Excel) then please supply 'as is' in the native document format.
Regardless of the application used other than Microsoft Office, when your electronic artwork is finalized, please 'Save as' or convert the images to one of the following formats (note the resolution requirements for line drawings, halftones, and line/halftone combinations given below):
EPS (or PDF): Vector drawings, embed all used fonts.
TIFF (or JPEG): Color or grayscale photographs (halftones), keep to a minimum of 300 dpi.
TIFF (or JPEG): Bitmapped (pure black & white pixels) line drawings, keep to a minimum of 1000 dpi.
TIFF (or JPEG): Combinations bitmapped line/half-tone (color or grayscale), keep to a minimum of 500 dpi.
Please do not:
• Supply files that are optimized for screen use (e.g., GIF, BMP, PICT, WPG); these typically have a low number of pixels and limited set of colors;
• Supply files that are too low in resolution;
• Submit graphics that are disproportionately large for the content.
Please make sure that artwork files are in an acceptable format (TIFF (or JPEG), EPS (or PDF) or MS Office files) and with the correct resolution. If, together with your accepted article, you submit usable color figures then Elsevier will ensure, at no additional charge, that these figures will appear in color online (e.g., ScienceDirect and other sites) in addition to color reproduction in print. Further information on the preparation of electronic artwork.
Elsevier's WebShop offers Illustration Services to authors preparing to submit a manuscript but concerned about the quality of the images accompanying their article. Elsevier's expert illustrators can produce scientific, technical and medical-style images, as well as a full range of charts, tables and graphs. Image 'polishing' is also available, where our illustrators take your image(s) and improve them to a professional standard. Please visit the website to find out more.
Ensure that each illustration has a caption. Supply captions separately, not attached to the figure. A caption should comprise a brief title (not on the figure itself) and a description of the illustration. Keep text in the illustrations themselves to a minimum but explain all symbols and abbreviations used.
Increased discoverability of research and high quality peer review are ensured by online links to the sources cited. In order to allow us to create links to abstracting and indexing services, such as Scopus, CrossRef and PubMed, please ensure that data provided in the references are correct. Please note that incorrect surnames, journal/book titles, publication year and pagination may prevent link creation. When copying references, please be careful as they may already contain errors. Use of the DOI is highly encouraged.
As a minimum, the full URL should be given and the date when the reference was last accessed. Any further information, if known (DOI, author names, dates, reference to a source publication, etc.), should also be given. Web references can be listed separately (e.g., after the reference list) under a different heading if desired, or can be included in the reference list.
This journal encourages you to cite underlying or relevant datasets in your manuscript by citing them in your text and including a data reference in your Reference List. Data references should include the following elements: author name(s), dataset title, data repository, version (where available), year, and global persistent identifier. Add [dataset] immediately before the reference so we can properly identify it as a data reference. The [dataset] identifier will not appear in your published article.
Reference to arXiv
As with unpublished results and personal communications, references to arXiv documents are not recommended in the reference list. Please make every effort to obtain the full reference of the published version of an arXiv document. If a reference to an arXiv document must be included in the references list it should follow the standard reference style of the journal and should include a substitution of the volume and page numbers with 'arXiv:YYMM.NNNN' or 'arXiv:arch-ive/YYMMNNN' for articles submitted to arXiv before April 2007.
Please ensure that the words 'this issue' are added to any references in the list (and any citations in the text) to other articles in the same Special Issue.
Reference Management Software
Most Elsevier journals have their reference template available in many of the most popular reference management software products. These include all products that support Citation Style Language styles, such as Mendeley and Zotero, as well as EndNote. Using the word processor plug-ins from these products, authors only need to select the appropriate journal template when preparing their article, after which citations and bibliographies will be automatically formatted in the journal's style.
Most Elsevier journals have their reference template available in many of the most popular reference management software products. These include all products that support Citation Style Language styles, such as Mendeley. Using citation plug-ins from these products, authors only need to select the appropriate journal template when preparing their article, after which citations and bibliographies will be automatically formatted in the journal's style. If no template is yet available for this journal, please follow the format of the sample references and citations as shown in this Guide. If you use reference management software, please ensure that you remove all field codes before submitting the electronic manuscript. More information on how to remove field codes from different reference management software.
Users of Mendeley Desktop can easily install the reference style for this journal by clicking the following link:
When preparing your manuscript, you will be able to select this style using the Mendeley plug-ins for Microsoft Word or LibreOffice.
Text: Indicate references by (consecutive) superscript arabic numerals in the order in which they appear in the text. The numerals are to be used outside periods and commas, inside colons and semicolons. For further detail and examples you are referred to the AMA Manual of Style, A Guide for Authors and Editors, Tenth Edition, ISBN 0-978-0-19-517633-9.
List: Number the references in the list in the order in which they appear in the text.
Reference to a journal publication:
1. Van der Geer J, Hanraads JAJ, Lupton RA. The art of writing a scientific article. J Sci Commun. 2010;163:51–59. https://doi.org/10.1016/j.Sc.2010.00372.
Reference to a journal publication with an article number:
2. 1. Van der Geer J, Hanraads JAJ, Lupton RA. The art of writing a scientific article. Heliyon. 2018;19:e00205. https://doi.org/10.1016/j.heliyon.2018.e00205.
Reference to a book:
3. Strunk W Jr, White EB. The Elements of Style. 4th ed. New York, NY: Longman; 2000.
Reference to a chapter in an edited book:
4. Mettam GR, Adams LB. How to prepare an electronic version of your article. In: Jones BS, Smith RZ, eds. Introduction to the Electronic Age. New York, NY: E-Publishing Inc; 2009:281–304.
Reference to a website:
5. Cancer Research UK. Cancer statistics reports for the UK. http://www.cancerresearchuk.org/aboutcancer/statistics/cancerstatsreport/; 2003 Accessed 13 March 2003.
Reference to a dataset:
[dataset] 6. Oguro, M, Imahiro, S, Saito, S, Nakashizuka, T. Mortality data for Japanese oak wilt disease and surrounding forest compositions, Mendeley Data, v1; 2015. https://doi.org/10.17632/xwj98nb39r.1.
Include interactive data visualizations in your publication and let your readers interact and engage more closely with your research. Follow the instructions here to find out about available data visualization options and how to include them with your article.
This journal encourages and enables you to share data that supports your research publication where appropriate, and enables you to interlink the data with your published articles. Research data refers to the results of observations or experimentation that validate research findings. To facilitate reproducibility and data reuse, this journal also encourages you to share your software, code, models, algorithms, protocols, methods and other useful materials related to the project.
If you have made your research data available in a data repository, you can link your article directly to the dataset. Elsevier collaborates with a number of repositories to link articles on ScienceDirect with relevant repositories, giving readers access to underlying data that gives them a better understanding of the research described.
For supported data repositories a repository banner will automatically appear next to your published article on ScienceDirect.In addition, you can link to relevant data or entities through identifiers within the text of your manuscript, using the following format: Database: xxxx (e.g., TAIR: AT1G01020; CCDC: 734053; PDB: 1XFN).
This journal supports Mendeley Data, enabling you to deposit any research data (including raw and processed data, video, code, software, algorithms, protocols, and methods) associated with your manuscript in a free-to-use, open access repository. During the submission process, after uploading your manuscript, you will have the opportunity to upload your relevant datasets directly to Mendeley Data. The datasets will be listed and directly accessible to readers next to your published article online.
To foster transparency, we encourage you to state the availability of your data in your submission. This may be a requirement of your funding body or institution. If your data is unavailable to access or unsuitable to post, you will have the opportunity to indicate why during the submission process, for example by stating that the research data is confidential. The statement will appear with your published article on ScienceDirect. For more information, visit the Data Statement page.
If the submission is accepted, the corresponding author will receive typeset page proofs online. Each corresponding author is expected to proofread all pages carefully and answer all queries posed by the copy editor. Page proofs should be reviewed by more than one person to enhance accuracy. All page proofs must be returned to the publisher within 72 hours of receipt to avoid delay in publication. The publisher does not send reminders; responding to the publisher with responses to author queries and requested changes is the corresponding author’s responsibility. The journal reserves final editorial approval for style, format, and grammar.
A reprint order form will either be e-mailed or accompany your copyedited manuscript and page proofs. You must return this form to the publisher with your corrected page proofs, whether or not you order reprints. The cost of reprints increases significantly if they are ordered after the initial print run. Reprints, except special orders of 100 or more, are available only for authors.
To submit an image for consideration as a cover, please send the files to the editorial office at email@example.com. Please use the subject header “Cover Image for Ophthalmology Glaucoma” so that the e-mail is appropriately flagged. Send the editorial office a JPG version of the image along with a photograph title, photographer and institutional affiliation, and equipment used to capture the image. If the photograph is appropriate, the editorial office will work with the submitter to generate appropriate file(s) for publication (see technical considerations below).If an image is selected for use as a potential cover image, Ophthalmology Glaucoma will need a completed copyright transfer form (see downloadable forms.) Once the form is received, the editorial office will assign the image for a future issue. Please be aware that it may be several months before it appears in print.
Technical ConsiderationsThe four-color printing process used in producing the journal cover requires high resolution files to achieve the best quality. Should an image be chosen for the cover, the file(s) should be available as minimally compressed JPG or ideally uncompressed (e.g., TIF or PSD) high resolution files of at least 8"x8" at 300 dpi. Screen grabs from video (even high definition video) do not upscale adequately for print and can appear blurred; similarly, output from most diagnostic instruments do not upscale well and can look pixelated.
Please do not perform any post-processing of the digital image other than light dusting and spot removal. sRGB colorspace is fine; do not convert to CMYK as this will be done by the publisher during pre-press processing. The high resolution files for final publication are usually too big to send by e-mail. A web-based large file transfer service (e.g., http://www.yousendit.com) can be used; please contact the editorial office (firstname.lastname@example.org) if you need assistance with transmitting large files.Copyright Considerations
Copyright for images must be transferred to the American Academy of Ophthalmology. The copyright transfer form must be signed by all listed authors. Please note that if the image has already appeared as part of an article in another journal or in a textbook, the author or photographer probably does not have the right to transfer the copyright to the AAO. Similarly, if the image has appeared as part of a photography contest (and especially if it won a prize), the conditions of contest participation should be clarified. The copyright transfer form should be submitted to the editorial office at email@example.com.In Press/Online Release
Availability of accepted article
This journal makes articles available online as soon as possible after acceptance. This concerns the accepted article (both in HTML and PDF format), which has not yet been copyedited, typeset or proofread. A Digital Object Identifier (DOI) is allocated, thereby making it fully citable and searchable by title, author name(s) and the full text. The article's PDF also carries a disclaimer stating that it is an unedited article. Subsequent production stages will simply replace this version.Manuscripts are available online as "in press" articles after completing the publisher’s proofing process. The online release is not a draft version since it is produced after all editorial and author corrections are made; however, there is a disclaimer in case a critical error is found. No routine editing will occur once an article appears online. The "in press" designation is removed as soon as the monthly issue is available online.
It is the corresponding author's responsibility that all editing be done at the time the original proofs are received from the publisher and that the publisher is notified immediately if the authors do not wish to have the "in press" article released online. All notifications regarding proof approvals, proof corrections, or requests that an article not be released "in press" prior to publication must come from the corresponding author and sent to Lisa Traynor (firstname.lastname@example.org).Data Sharing
To promote transparency and opportunities for further research, authors of work published in Ophthalmology Glaucoma are encouraged to provide access to relevant datasets in compliance with contemporary reporting standards. Authors may use domain-specific public archives (for example, ClinicalTrials.gov, GenBank, Protein Data Bank), or generic databases (for example, Dataverse, Dryad, Mendeley, or the Open Science Framework, or an institutional repository).
For additional information, please consult:
Taichman DB, Backus J, Baethge C, et al. Sharing Clinical Trial Data: A Proposal From the International Committee of Medical Journal Editors. JAMA 2016;315(5):467-468.
If you have questions about the submission process or are unable to access the system, please contact the editorial office by e-mail at email@example.com or by phone at 415-447-0261.Communication about manuscripts occur primarily through email and only with corresponding authors, so it is important for authors to keep their contact information (address, institution, phone numbers, and e-mail address) current.